Canada Pension Plan Investment Board Buys 89,235 Shares of Moderna, Inc. (NASDAQ:MRNA)

Canada Pension Plan Investment Board lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 24.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 454,407 shares of the company’s stock after acquiring an additional 89,235 shares during the quarter. Canada Pension Plan Investment Board’s holdings in Moderna were worth $18,894,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MRNA. Wilmington Savings Fund Society FSB boosted its position in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares during the period. Venturi Wealth Management LLC boosted its holdings in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after buying an additional 664 shares during the period. Compass Planning Associates Inc bought a new position in Moderna in the 4th quarter worth $37,000. Crowley Wealth Management Inc. bought a new stake in Moderna during the fourth quarter valued at about $41,000. Finally, MassMutual Private Wealth & Trust FSB lifted its position in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after acquiring an additional 389 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on MRNA shares. UBS Group decreased their target price on Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. The Goldman Sachs Group cut shares of Moderna from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. Royal Bank of Canada restated a “sector perform” rating and set a $40.00 target price on shares of Moderna in a research report on Tuesday, February 18th. Citigroup assumed coverage on shares of Moderna in a report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 price target on the stock. Finally, Bank of America cut their price objective on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $58.70.

Moderna Price Performance

Moderna stock opened at $24.72 on Monday. The stock has a market cap of $9.56 billion, a price-to-earnings ratio of -2.66 and a beta of 2.23. The firm has a 50-day moving average of $30.84 and a two-hundred day moving average of $39.49. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.